Literature DB >> 3926233

Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects.

R J Polson, A Jawed, A Bomford, H Berry, R Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3926233      PMCID： PMC1416290          DOI： 10.1136/bmj.291.6493.448

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  Serum ferritin concentration as an index of storage iron in rheumatoid arthritis.

Authors:  D P Bentley; P Williams
Journal:  J Clin Pathol       Date:  1974-10       Impact factor: 3.411

2.  Management of nausea and vomiting in the cancer patient.

Authors:  S Frytak; C G Moertel
Journal:  JAMA       Date:  1981 Jan 23-30       Impact factor: 56.272

3.  The importance of iron in rheumatoid disease.

Authors:  D R Blake; N D Hall; P A Bacon; P A Dieppe; B Halliwell; J M Gutteridge
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

4.  Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent.

Authors:  N Bowern; I A Ramshaw; I A Clark; P C Doherty
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307
  4 in total
  11 in total

1.  Role of myeloperoxidase in intracellular and extracellular chemiluminescence of neutrophils.

Authors:  H L Nurcombe; S W Edwards
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

2.  Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis.

Authors:  S W Edwards; V Hughes; J Barlow; R Bucknall
Journal:  Biochem J       Date:  1988-02-15       Impact factor: 3.857

3.  Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.

Authors:  David T Dexter; Sarah A Statton; Charlotte Whitmore; Wolfhardt Freinbichler; Peter Weinberger; Keith F Tipton; Laura Della Corte; Roberta J Ward; Robert R Crichton
Journal:  J Neural Transm (Vienna)       Date:  2010-12-17       Impact factor: 3.575

Review 4.  Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment.

Authors:  G Vreugdenhil; A J Swaak
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

Review 5.  Deferoxamine (desferrioxamine). New toxicities for an old drug.

Authors:  Y Bentur; M McGuigan; G Koren
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

6.  Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis.

Authors:  C Salvarani; R Baricchi; D Lasagni; L Boiardi; R Piccinini; C Brunati; P Macchioni; I Portioli
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

7.  Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.

Authors:  E E Voest; J P Neijt; J E Keunen; A W Dekker; B S van Asbeck; J W Nortier; F E Ros; J J Marx
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.

Authors:  S Merali; K Chin; L Del Angel; R W Grady; M Armstrong; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 9.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 10.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.